Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
International Journal of Clinical Oncology|February 15, 2018
Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in JapanMegumi Hirobe, Toshiaki Tanaka, Tetsuya Shindo, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 4, 2015
[Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma]Ryuta Inoue, Hiroshi Kitamura, Tetsuya Shindo, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 3, 2021
Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective studyTetsuya Shindo, Kohei Hashimoto, Toshiaki Tanaka, et al.
World Journal of Urology|November 6, 2013
Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC)Tetsuya Shindo, Naoya Masumori, Hiroshi Kitamura, et al.
Case Reports in Oncological Medicine|November 18, 2020
Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid CancerHajime Nakamura, Kohichi Takada, Kazuyuki Murase, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 2, 2022
Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective studyTetsuya Shindo, Takeshi Maehana, Toshiaki Tanaka, et al.
Journal of Geriatric Oncology|January 10, 2025
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective studyTetsuya Shindo, Kohei Hashimoto, Toshiki Kenuka, et al.
Haematologica|September 2, 2018
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signalingKazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, et al.
Anticancer Research|February 29, 2024
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based ChemotherapyTetsuya Shindo, Kohei Hashimoto, Atsushi Takahashi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 3, 2023
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapyManabu Okada, Tetsuya Shindo, Keiko Fujino, et al.
Pageof 11